Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system). - RIMAL1

Radboud Universitair Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月9日

适应症

试验速览

暂无简介。

•- Not fit (mentally or physically) to undergo the proposed treatment.
•- Patients with connective tissue diseases (inflammatory myopathy (polymyositis
•and ermatomyositis), systemic lupus erythematosus, Sjögren syndrome, systemic
•sclerosis, antisynthetase syndrome, rheumatoid arthritis, severe psoriasis and
•mixed CTDs), vasculitis (granulomatosis with polyangiitis (Wegener*s
•granulomatosis), microscopic polyangiitis, eosinophilic granulomatosis with
•polyangiitis (Churg-Strauss syndrome), severe Behçet disease, Takayasu
•arteritis, giant cell arteritis, Buerger disease, Kawasaki disease,
•polyarteritis nodosa, severe immunoglobulin A (IgA) vasculitis (Henoch-
•Schönlein purpura), severe cutaneous vasculitis, polymyalgia rheumatica, severe
•cryoglobulinaemia and undifferentiated systemic vasculitis) and other
•autoimmune diseases (primary biliary cirrhosis, severe autoimmune hepatitis,
•multiple sclerosis, severe antiphospholipid syndrome, myasthenia gravis,
•Guillain-Barré syndrome, inflammatory bowel disease, Miller-Fisher syndrome,
•Vogt-Koyanagi-Harada syndrome, eosinophilic fasciitis (Shulman syndrome),
•relapsing polychondritis and severe autoinflammatory diseases) ( Martins et al.
•- Sensory or motor peripheral neuropathy > grade 2.

发起方